Dermatology

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against InMode, Lantronix, Palo Alto Networks, and Snowflake and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 5, 2024
Complaint, Palo Alto Networks, Internet, Intelligence, Dentist, PANW, FDA, Transport, Internet of things, Snowflake Inc., Injury, Confidentiality, Growth, Federation, IPO, City, Food and Drug Administration, News, SNOW, EPS, IOT, Defendant, Dermatology, P.C, Audit

InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • The customers also stated that InMode offered to replace defective products on the condition of signing confidentiality agreements with non-disparagement clauses.
  • which lowered credit consumption.”  On this news, the price of Snowflake Class A common stock fell nearly 28% over several trading sessions, damaging investors.

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 4, 2024
European Commission, Research, Investment, Research and development, Dialysis, Marketing, CSL, Sale, Conference, HCR, Safety, Civil service commission, Therapy, CSL Vifor, Administration, Patient, Clinical trial, ESRD, G&A, Clutch (eggs), Itch, Dermatology

STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • The Company enrolled 214 patients and expects topline efficacy and safety results from KOURAGE 1 Part A in the third quarter of 2024.
  • Final topline results from the first pivotal study are expected by the end of 2025 with the second pivotal study results in early 2026.
  • Wholesalers shipped 110,700 vials to dialysis centers during the fourth quarter of 2023 (an increase of 22% vs. the third quarter of 2023), the majority of which were vials reallocated within the Fresenius network of clinics.
  • Revenues: Total revenue was $3.0 million and $3.3 million for the three months ended December 31, 2023 and 2022, respectively.

Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting

Retrieved on: 
Monday, March 4, 2024
SAN, Dermatology, High, Safety, AAD, Patient, Pharmacodynamics, Phase 1, American Academy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced two clinical data presentations at the American Academy of Dermatology Annual Meeting taking place March 8-12, 2024, in San Diego, CA.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced two clinical data presentations at the American Academy of Dermatology Annual Meeting taking place March 8-12, 2024, in San Diego, CA.
  • Details regarding the presentations are as follows:
    Title: Efficacy and Safety of ESK-001, a Highly Selective Oral TYK2 Inhibitor, in a Phase 2 Study in
    Title: Pharmacokinetic and Pharmacodynamic Characteristics of ESK-001, an Oral Allosteric TYK2 Inhibitor, in Phase 1 Healthy Volunteer Trials
    Alumis will also host a virtual investor event to review the ESK-001 Phase 2 clinical data being presented at AAD on March 9 at 5:00 p.m. PT.
  • To access the live webcast, please register by visiting the Events page on the Alumis website.

Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting 

Retrieved on: 
Monday, March 4, 2024
SAN, AAD, MHS, American Academy of Dermatology, Dermatology, MD, American Academy

SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

Key Points: 
  • SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
  • Dr. Gilly Munavalli, MD, MHS, FACMS will present Sofwave’s new Pure Impact™ Strength and Muscle Toning module to fellow dermatologists and meeting participants for the first time in the United States.
  • Sofwave Event Detail at AAD:

INMODE LTD. (NASDAQ: INMD) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against InMode Ltd.

Retrieved on: 
Monday, March 4, 2024
Court, Action Replay, Dentist, News, Advertising, Complaint, District court, Food and Drug Administration, Dermatology

If you purchased or acquired InMode common stock, and/or would like to discuss your legal rights and options please visit InMode Ltd.

Key Points: 
  • If you purchased or acquired InMode common stock, and/or would like to discuss your legal rights and options please visit InMode Ltd.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 15, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against InMode, Lantronix, and Palo Alto Networks and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024
Complaint, Palo Alto Networks, Internet, Intelligence, Dentist, PANW, FDA, Transport, Internet of things, Confidentiality, Injury, News, Growth, Federation, City, Food and Drug Administration, EPS, IOT, Defendant, Dermatology, P.C

InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • On this news, the price of Palo Alto Networks, Inc. common stock declined by $104.12 per share, or approximately 28%, on February 21, 2024.
  • For more information on the Palo Alto Networks class action go to: https://bespc.com/cases/PANW

INMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that InMode Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, February 28, 2024
Court, Person, Dentist, FDA, Confidentiality, Injury, Complaint, Food and Drug Administration, Dermatology

InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

Retrieved on: 
Tuesday, February 27, 2024
Therapy, Dermatology, Webcast, Skin, Conference

WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference, which will be held in Boston, Massachusetts.

Key Points: 
  • WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference, which will be held in Boston, Massachusetts.
  • The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com .
  • A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against LuxUrban, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 27, 2024
Complaint, Analysis, Letter, Dentist, FDA, News, Confidentiality, Injury, Royalton Hotel, Food and Drug Administration, Result, Defendant, Dermatology, P.C

On January 17, 2024, Bleeker Street Research published a report, which alleged that the Company had not actually signed a lease with the Royalton Hotel.

Key Points: 
  • On January 17, 2024, Bleeker Street Research published a report, which alleged that the Company had not actually signed a lease with the Royalton Hotel.
  • The report started the owner of the Royalton hotel building confirmed LuxUrban never actually signed a lease, nor even provided a Letter of Credit.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

INMODE LTD. (NASDAQ: INMD) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against InMode Ltd.

Retrieved on: 
Monday, February 26, 2024
Court, Action Replay, Dentist, News, Advertising, Complaint, District court, Food and Drug Administration, Dermatology

If you purchased or acquired InMode common stock, and/or would like to discuss your legal rights and options please visit InMode Ltd.

Key Points: 
  • If you purchased or acquired InMode common stock, and/or would like to discuss your legal rights and options please visit InMode Ltd.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 15, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.